Monday 20 August 2018 ,
Monday 20 August 2018 ,
Latest News
  • Movement for safe roads: 25 students get bail
  • Bangabandhu’s killer Rashed Chowdhury to be brought back: Law Minister
  • AL plotting to keep BNP away from election: Fakhrul
  • Multi-storey buildings to replace city slums: PM
  • Hills turn bloody: 31 killed since December last
5 February, 2018 00:00 00 AM

Cancer blood test ‘enormously exciting’

BBC News Health
Cancer blood test ‘enormously exciting’

James Gallagher

Scientists have taken a step towards one of the biggest goals in medicine - a universal blood test for cancer.

A team at Johns Hopkins University has trialled a method that detects eight common forms of the disease.

Their vision is an annual test designed to catch cancer early and save lives. UK experts said it was "enormously exciting".

However, one said more work was needed to assess the test's effectiveness at detecting early-stage cancers.

Tumours release tiny traces of their mutated DNA and proteins they make into the bloodstream.

The CancerSEEK test looks for mutations in 16 genes that regularly arise in cancer and eight proteins that are often released.

It was trialled on 1,005 patients with cancers in the ovary, liver, stomach, pancreas, oesophagus, colon, lung or breast that had not yet spread to other tissues.

Overall, the test found 70% of the cancers.

Dr Cristian Tomasetti, from Johns Hopkins University School of Medicine, told the BBC: "This field of early detection is critical.

"I think this can have an enormous impact on cancer mortality."

The earlier a cancer is found, the greater the chance of being able to treat it.

Five of the eight cancers investigated have no screening programmes for early detection.

In some cases, the test also provided information about the tissue-of-origin of the cancer - but not all.

Pancreatic cancer has so few symptoms and is detected so late that four in five patients die in the year they are diagnosed.

Finding tumours when they could still be surgically removed would be "a night and day difference" for survival, said Dr Tomasetti.

CancerSEEK is now being trialled in people who have not been diagnosed with cancer, which will be the real test of its usefulness.

The hope is it can complement other screening tools such as mammograms for breast cancer and colonoscopies for colorectal cancer.

Dr Tomasetti said: "We envision a blood test we could use once a year."

Universal test?

The CancerSEEK test, reported in the journal Science, is novel because it hunts for both the mutated DNA and the proteins.

Increasing the number of mutations and proteins being analysed would allow it to test for a wider range of cancers.

Dr Gert Attard, team leader in the Centre for Evolution and Cancer at the Institute of Cancer Research, London, and consultant medical oncologist at the Royal Marsden NHS Foundation Trust, told the BBC: "This is of massive potential.

 

"I'm enormously excited. This is the Holy Grail - a blood test to diagnose cancer without all the other procedures like scans or colonoscopy."

He said "we're very close" to using blood tests to screen for cancer as "we have the technology".

But he cautioned there was still uncertainty about what to do when a cancer was diagnosed.

In some cases, the treatment may be worse than living with a cancer that is not immediately life-threatening.

Men can already have slow growing prostate cancers closely monitored rather than treated.

"When we detect cancer in a different way, we can't take for granted that everyone will need treatment," Dr Attard said.

Early stage cancers

Prof Richard Marais, from Cancer Research UK, said it would take time to prove that it worked as an early diagnosis for cancer - at least five to six years.

"Detecting cancer early, before the disease has spread is one of the most powerful ways to improve cancer survival and this interesting research is a step towards being able to do this earlier than is currently possible."

Paul Pharoah, professor of cancer epidemiology at the University of Cambridge, said more work was needed to assess how the test performs when cancers are less advanced.

He said: "Demonstrating that a test can detect advanced cancers does not mean that the test will be useful in detecting early stage symptomatic cancer, much less pre-symptomatic cancer. The sensitivity for the stage 1 cancers in the study was only 40%."

And Dr Mangesh Thorat from the Centre for Cancer Prevention, Queen Mary University of London, said it looked promising "but with several caveats"

"A significant amount of further research is needed before we can even contemplate how this might play out in screening settings," he said.

"This is only a case-control study, and therefore needs further evaluation in large cohorts more representative of general population where such screening might be introduced."

The cost of CancerSEEK is less than $500 (£360) per patient, which is around the same price as a colonoscopy.

Comments

Most Viewed
Digital Edition
More story
From the Editor

From the Editor

The eye is the most vital of all the sense organs of humankind. Through the eye we can see the most precious of the gifts of God; this most bounteous…
Retinal disorders

Retinal disorders

The retina is the light-sensitive membrane on the inner surface of the back of the eye. The optic nerve extends from the brain to about the center of…
Glaucoma

Glaucoma

Glaucoma is a serious eye disease and a common cause of blindness. It is responsible for 20% of blindness in Singapore. Glaucoma is caused by damage to…
Cataracts

Cataracts

A cataract is a clouding of the eye's natural lens, which lies behind the iris and the pupil. The lens works much like a camera lens, focusing light…
Refractive disorders

Refractive disorders

Normally, the eye creates a clear image because the cornea and lens bend (refract) incoming light rays to focus them on the retina. The shape of the cornea…
Autoimmune response contributes to vision loss in glaucoma patients

Autoimmune response contributes to vision loss in glaucoma patients

A research team from Massachusetts Eye and Ear and MIT has shown that immune cells in the eye that developed in response to early exposure to bacteria…
How blue light from smartphones can speed up blindness

How blue light from smartphones can speed up blindness

Staring at your mobile phone or laptop could speed up blindness, according to scientists.   A new study by Toledo University in Ohio found that blue…
Guide to personality disorders

Guide to personality disorders

What is a personality disorder? These mental health conditions affect your everyday life and relationships. They’re about how you think, feel, and…
Preventing and treating non-
communicable diseases

Preventing and treating non- communicable diseases

We aim to assess the burden of non-communicable diseases (NCDs) in Bangladesh, document the epidemiology and risk factors of the most common NCDs, and…
Occupational therapy for Chiari Malformation (CM)

Occupational therapy for Chiari Malformation (CM)

Chiari malformation is a problem with the structures at the back of the brain. An area of the brain called the cerebellum normally sits inside the back…
Regular exercise 'best for mental health'

Regular exercise 'best for mental health'

Regular physical activity lasting 45 minutes three to five times a week can reduce poor mental health - but doing more than that is not always beneficial,…
Stem cells restore some vision in blind mice

Stem cells restore some vision in blind mice

Scientists say they have restored some degree of vision in blind lab mice, by activating stem cells in their eyes. The procedure is the first of its kind…
FDA approves Perseris (risperidone) for the treatment of schizophrenia in adults

FDA approves Perseris (risperidone) for the treatment of schizophrenia in adults

Indivior PLC recently announced that the U.S. Food and Drug Administration (FDA) has approved Perseris, the first once-monthly subcutaneous risperidone-containing,…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting